Atossa Therapeutics
Atossa is a Seattle company developing oral endoxifen, the active metabolite of tamoxifen, for breast cancer prevention and treatment and for reducing dense breast tissue.
Overview
Atossa Therapeutics, founded in 2009 in Seattle, develops (Z)-endoxifen, the most active metabolite of tamoxifen, as an oral drug that bypasses the CYP2D6 metabolism that makes tamoxifen variable between patients. It is tested to reduce mammographic breast density in women at high risk, in the window before surgery, and alongside CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer. Its trials are registered on ClinicalTrials.gov under Atossa as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyForward Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.